Valeant Pharmaceuticals
Valeant to spend $27.5M to upgrade Canadian manufacturing plants
Investments to be made in Manitoba and Quebec.
Valeant invests $8M in Manitoba manufacturing plant
Company to transfer North American production of Xifaxan and Apriso to Steinbach facility.
Valeant to cut all ties with Philidor
Hopes to minimize disruption for patients .